On-the-spot detection of diabetic retinopathy with the handheld AI fundus camera

Exceptional clinical accuracy and precision in diabetic retinopathy detection*




This new FDA clearance is based on two large-scale prospective phase-III studies, in which AEYE-DS demonstrated best-in-class efficacy and imageability. Diagnostic sensitivity was in the range of 92%-93% and specificity was in the range of 89%-94%. In both studies, over 99% of patients received a diagnostic result. The AI produced its diagnostic results using only a single image from each eye, rarely requiring dilation.

Empowering Early Detection with Optomed Aurora AEYE

The Optomed Aurora AEYE sets a new standard in diabetic eye screening offering fast and high-quality screening of diabetic retinopathy with on-the-spot results. Screening with unmatched accuracy and precision can be performed by any trained healthcare professional. Our solution is here to close the care-gap and drive improvements in patient outcomes.

The workflow from image capture to result delivery is simple and fast. The AI needs only one image per eye for the analysis and the screening result will be delivered to the camera display in less than 60 seconds.

Visit our US site

Experience the future of DR screening with us

Fill up the form and we’ll contact you as soon as possible.
Notice that this solution is only available in the US.


    I have read Optomed's Privacy Statement and I accept the policy.

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


    [* Optomed Aurora AEYE FDA study https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K240058]